Posts by: Alice Melão

News

The immune checkpoint inhibitor Bavencio (avelumab) failed to do a better job than the chemotherapy Taxotere (docetaxel) at improving lung cancer patients’ survival, a Phase 3 clinical trial shows. Those in ... Read more

February 26, 2018February 26, 2018

Bristol-Myers, Nektar Developing Cancer Therapy to Be Used with Checkpoint Inhibitors

News

Bristol-Myers Squibb and Nektar Therapeutics are working together on a cancer therapy that can be used in combination with immune checkpoint inhibitors Bristol-Meyers is developing. The hope is that the therapy, NKTR-214, can ... Read more

February 16, 2018February 16, 2018

73% of Kidney Cancer Patients Respond to Inlyta-Keytruda Combo, Trial Shows

News

Seventy-three percent of patients with kidney cancer that appeared in other parts of their body after their main tumor had been removed responded to a combination of Inlyta (axitinib) and Keytruda (pembrolizumab), ... Read more

February 7, 2018February 7, 2018

Opdivo-Yervoy Combo Shows Promise for Treating Certain Colorectal Cancers

News

A combination of the immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) induces durable responses in patients with metastatic colorectal cancer with certain genetic features, a Phase 2 clinical trial shows. ... Read more

January 30, 2018January 30, 2018

Treos Bio’s Cancer Vaccine Cleared to Enter Phase 1 Trial for Advanced Colon Cancer

News

A Phase 1 clinical trial sponsored by Treos Bio will soon begin to evaluate the company’s PolyPEPI 1018 cancer vaccine for the treatment of metastatic colorectal cancer (mCRC). The start of the trial ... Read more

January 18, 2018

Phase 1/2a Trial Testing VBI-1901 in Glioblastoma Mulitforme Doses First Patient

News

The Phase 1/2a clinical trial evaluating VBI Vaccines‘ cancer vaccine, VBI-1901, in recurrent glioblastoma multiforme (GBM) has dosed its first patient, the company announced. This follows the clearance of an Investigative New ... Read more

January 17, 2018January 17, 2018

Providence Cancer Institute, Nanobiotix Partner for Preclinical Study of NBTXR3 in Pancreatic Cancer

News

A preclinical study testing Nanobiotix’s radiotherapy enhancer NBTXR3 in pancreatic cancers is underway as part of a collaboration with one of the world’s leading oncological research centers, the Providence Cancer Institute, ... Read more

January 11, 2018January 11, 2018

FDA Grants Breakthrough Therapy Status to Lenvima-Keytruda Combo for Advanced Kidney Cancer

News

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eisai’s Lenvima (lenvatinib), in combination with Merck’s Keytruda (pembrolizumab), to treat patients with advanced renal cell carcinoma (RCC). The ... Read more

January 9, 2018January 9, 2018

Initial Safety Review Supports Expansion of MAGE-A10 SPEAR T-Cell Triple Tumor Phase 1 Trial

News

An initial review of two ongoing Phase 1 trials evaluating SPEAR T-cells targeting MAGE-A10 in non-small cell lung cancer (NSCLC) and in bladder, melanoma, and head and neck cancers, revealed ... Read more

January 4, 2018

First Patient Dosed in Phase 3 Trial of BeiGene’s Therapy Candidate for Advanced Liver Cancer

News

Investigators have dosed the first patient in a global Phase 3 trial evaluating the PD-1 inhibitor tislelizumab (BGB-A317) as a first-line therapy for advanced hepatocellular carcinoma (HCC) — the most common ... Read more